Data from Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8&lt;sup&gt;+&lt;/sup&gt; T-Cell–Dependent Tumor Activity

Exploring foci of: doi.org Data from Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8&lt;sup&gt;+&lt;/sup&gt; T-Cell–Dependent Tumor Activity March 2023 • Tsubasa Watanabe, Simone Gaedicke, Elena Guffart, Elke Firat, Gabriele Niedermann &lt;div&gt;AbstractPurpose:&lt;p&gt;There is growing interest in combinations of immunogenic radiotherapy (RT) and immune checkpoint blockade, but clinical responses are still limited. Therefore, we tested the triple therapy with an inhibitor of the indoleamine 2,3-dioxygenase pathway, which like immune checkpoints, downregulates the antitumor immune response.&lt;/p&gt;Experimental Design:&lt;p&gt;Triple treatment with hypofractionated RT (hRT) + anti-PD-1 antibody (αPD1) + indoximod was compared with the respecti… Open Article Page

Blockade Immune System Apoptosis Medicine Biology Internal Medicine Immunology Biochemistry Open Article